BioCryst reports forodesine data for CTCL

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) said once-daily oral forodesine produced an overall response rate of 11%, with 11 partial responses, plus 56 cases of stable disease in 101 patients in a Phase II trial to treat cutaneous T cell lymphoma (CTCL). BioCryst said the sample size was too small to determine statistical significance of the data. The company said the response rate may reflect the effect of heavy pretreatment with multiple prior lines of therapy. The open-label, international trial enrolled 144 patients with stage IIB-IVA CTCL who had received at least three prior systemic therapies. ...